| 101 |
26457538 | Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. | 2015 Nov 3 |
2 |
| 102 |
26474470 | Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects. | 2015 |
2 |
| 103 |
26616595 | Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin. | 2015 Dec |
4 |
| 104 |
26867302 | [How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES]. | 2015 Dec |
2 |
| 105 |
26962596 | | 2015 Aug |
1 |
| 106 |
26962605 | | 2015 Aug |
1 |
| 107 |
30298777 | Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations. | 2015 May |
1 |
| 108 |
23668534 | Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. | 2014 Feb |
1 |
| 109 |
24186866 | Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. | 2014 Feb |
1 |
| 110 |
24517395 | Adding a DPP-4 inhibitor to metformin therapy may be safer than you think. | 2014 May |
1 |
| 111 |
24639059 | The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis. | 2014 Jul |
1 |
| 112 |
24647737 | Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. | 2014 Aug |
1 |
| 113 |
24682379 | Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. | 2014 Jul |
2 |
| 114 |
24824197 | Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. | 2014 Dec |
1 |
| 115 |
24827939 | Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study. | 2014 Oct |
4 |
| 116 |
24829965 | The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. | 2014 May |
1 |
| 117 |
24863949 | Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. | 2014 Oct |
1 |
| 118 |
25089625 | Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. | 2014 |
4 |
| 119 |
25089916 | Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome. | 2014 Nov |
1 |
| 120 |
25180036 | Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity. | 2014 |
3 |
| 121 |
25279360 | Acute myocardial infarction associated to DPP-4 inhibitors. | 2014 |
2 |
| 122 |
25597711 | [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact]. | 2014 Oct-Dec |
1 |
| 123 |
23241069 | A review of the efficacy and safety of oral antidiabetic drugs. | 2013 Mar |
1 |
| 124 |
23373842 | Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. | 2013 Mar |
2 |
| 125 |
23421949 | Efficacy and safety of Jentadueto® (linagliptin plus metformin). | 2013 Mar |
2 |
| 126 |
23539735 | CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. | 2013 Jun |
3 |
| 127 |
23579178 | Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. | 2013 Sep |
1 |
| 128 |
23662021 | Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial. | 2013 Jan |
2 |
| 129 |
23680741 | Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? | 2013 Apr |
1 |
| 130 |
23730503 | Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. | 2013 Jun |
4 |
| 131 |
23870706 | Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients. | 2013 Nov |
3 |
| 132 |
24137964 | [A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition]. | 2013 |
1 |
| 133 |
24640684 | [Hypoglycemia in patients with type 2 diabetes mellitus: safe solution of the dangerous problem]. | 2013 |
1 |
| 134 |
20455069 | Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. | 2012 Dec |
1 |
| 135 |
22149373 | Metformin + saxagliptin for type 2 diabetes. | 2012 Jan |
2 |
| 136 |
22153807 | Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. | 2012 Jan |
3 |
| 137 |
22171692 | The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. | 2012 Jun |
3 |
| 138 |
22197148 | DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. | 2012 Apr |
1 |
| 139 |
22324384 | Dipeptidyl peptidase-4 inhibitors: 3 years of experience. | 2012 Apr |
1 |
| 140 |
22340932 | Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. | 2012 Mar |
1 |
| 141 |
22419732 | Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. | 2012 May |
1 |
| 142 |
22486277 | Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. | 2012 Aug |
1 |
| 143 |
22683131 | Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. | 2012 Jun 16 |
2 |
| 144 |
22736406 | Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. | 2012 Nov |
1 |
| 145 |
30764006 | Saxagliptin plus metformin combination therapy. | 2012 Mar |
1 |
| 146 |
20152998 | Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. | 2011 Jan |
4 |
| 147 |
21205107 | Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. | 2011 Mar |
2 |
| 148 |
21319871 | Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. | 2011 Feb 12 |
1 |
| 149 |
21472661 | A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*. | 2011 Jul |
1 |
| 150 |
21727749 | Diabetes and Ramadan: an update on use of glycemic therapies during fasting. | 2011 Jul-Aug |
1 |